Dmitry Balyasny’s Soleno Therapeutics SLNO Stock Holding History

Dmitry Balyasny’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-227,751	Closed	-$10.5M	–	3474
2025 Q4	$10.5M	Sell	227,751 -432,814	-66%	-$23.7M	0.01%	998
2025 Q3	$44.7M	Buy	660,565 +298,960	+83%	+$22.2M	0.06%	399
2025 Q2	$30.3M	Buy	361,605 +344,273	+1,986%	+$25.8M	0.05%	515
2025 Q1	$1.24M	Sell	17,332 -243,993	-93%	-$11.9M	﹤0.01%	1904
2024 Q4	$11.7M	Buy	+261,325	New	+$13.5M	0.02%	893
2024 Q3	–	Sell	-247,214	Closed	-$10.1M	–	3128
2024 Q2	$10.1M	Buy	247,214 +95,596	+63%	+$4.05M	0.02%	886
2024 Q1	$6.49M	Sell	151,618 -775,258	-84%	-$35.1M	0.01%	1117
2023 Q4	$37.3M	Buy	926,876 +468,053	+102%	+$13.3M	0.07%	356
2023 Q3	$13.5M	Buy	+458,823	New	+$2.78M	0.03%	723

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Dmitry Balyasny's SLNO Position: Q1 2026 in Review

Dmitry Balyasny sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 227,751 shares — an estimated $10.5M sold.

Dmitry Balyasny first reported a position in SLNO in Q3 2023 and held it in 9 quarters. The position peaked at $44.7M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Dmitry Balyasny reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
Dmitry Balyasny sold 227,751 Soleno Therapeutics shares in Q1 2026, an estimated $10.5M.
Dmitry Balyasny first reported a position in Soleno Therapeutics in Q3 2023 and held it in 9 quarters.
Dmitry Balyasny's Soleno Therapeutics position peaked at $44.7M in Q3 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.